AIM ImmunoTech (AIM) Q1 2026 earnings summary

Executive summary

• Focused on developing Ampligen for late-stage pancreatic cancer, with ongoing Phase 2 DURIPANC trial and plans for a Phase 3 study in partnership with Thermo Fisher Scientific.

• Ampligen also being evaluated for other cancers, ME/CFS, post-COVID conditions, and as a broad-spectrum antiviral.

• Company faces significant liquidity challenges and risks related to NYSE American listing compliance.

Financial highlights

• Net loss for Q1 2026 was $3.0 million, an improvement of $0.7 million from Q1 2025, driven by lower R&D and G&A expenses.

• Total revenues were $22,000, up 37.5% year-over-year.

• Cash and cash equivalents increased to $5.8 million as of March 31, 2026, from $3.0 million at year-end 2025.

• Operating loss narrowed to $2.2 million from $3.6 million year-over-year.

• Significant non-recurring losses: $468,000 on warrant reclassification and $32,000 on warrant issuance.

Outlook and guidance

• Ongoing focus on advancing Ampligen for pancreatic cancer, with Phase 2 DURIPANC trial nearing full enrollment and Phase 3 planning underway.

• Company must raise additional capital to meet NYSE American equity requirements and fund operations.

• Short-term working capital needs estimated at $7.2–$10.8 million over the next 12 months.